Catecholamine storage vesicle protein expression in genetic hypertension

Blood Pressure

Volumn 8, Issue 5-6, 1999, Pages 285-295

  O'Connor, Daniel T ^a,c   Takiyyuddin, Marwan A ^a,c   Printz, Morton P ^b   Dinh, Thai Q ^a,c   Barbosa, Juan A ^a,c   Rozansky, David J ^a,c   Mahata, Sushil K ^a,c   Wu, Hongjiang ^a,c   Kennedy, Brian P ^a   Ziegler, Michael G ^a   Wright, Fred A ^e   Schlager, Gunther ^d   Parmer, Robert J ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b San Diego   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF KANSAS   (United States)

Author keywords

Adrenal medulla; Catecholamine; Chromaffin; Chromogranin; Dopamine hydroxylase; Hypertension; Secretogranin

Indexed keywords

CATECHOLAMINE; CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN B; CYCLOPHILIN; DOPAMINE BETA MONOOXYGENASE; NORADRENALIN; PROTEIN DERIVATIVE;

ADRENAL MEDULLA; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE LOCUS; GENE OVEREXPRESSION; HEREDITARY HYPERTENSION; MALE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0033507145     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370599439508     Document Type: Article

References (55)

1. Hunt SC, Williams RR. Genetic factors in human hypertension. In: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell Scientific, 1994: 519-38.
2. Kailasam MT, O'Connor DT, Parmer RJ. Hereditary intermediate phenotypes in African-American hypertension. Ethn Health 1996; 1: 133-44.
3. Dao TT, Kailasam MT, Parmer RJ, et al. Expression of altered alpha-2-adrenogeric phenotypic traits in normotensive humans at genetic risk of hereditary (essential) hypertension. J Hypertens 1998; 16: 779-92.
4. Williams GH, Dluhy RG, Lifton RP, et al. Non-modulation as an intermediate phenotype in essential hypertension. Hypertension 1992; 20: 788-96.
5. Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JA, Parmer RJ, O'Connor DT. Chromogranin A: storage and release in hypertension. Hypertension 1990; 15: 237-46.
6. Takiyyuddin MA, Cervenka JH, Sullivan PA, Pandian MR, Barbosa JA, O'Connor DT. Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 1990; 81: 185-95.
7. Takiyyuddin MA, Parmer RJ, Kailasam MT, et al. Chromogranin A in human hypertension: influence of heredity. Hypertension 1995; 26: 213-20.
8. Videen JS, Mezger MS, Chang YM, O'Connor DT. Calcium and catecholamine interactions with adrenal chromogranins: comparison of driving forces in binding and aggregation. J Biol Chem 1992; 267: 3066-73.
9. Parmer RJ, Xi XP, Wu HJ, Helman LJ, Petz LN. Secretory protein traffic. Chromogranin A contains a dominant targeting signal for the regulated pathway. J Clin Invest 1993; 92: 1042-54.
10. Eskeland NL, Zhou A, Dinh TQ, et al. Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases. J Clin Invest 1996; 98: 148-56.
11. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 1992; 41: 9-18.
12. Helle KB, Marley PD, Hogue-Angeletti R, et al. Chromogranin A: secretion of processed products from the stimulated retrogradely perfused bovine adrenal gland. J Neuroendocrinol 1993; 5: 413-20.
13. Mahata SK, O'Connor DT, Mahata M, et al. Novel autocrine feedback control of catecholamine release: a discrete chromogranin A fragment is a non-competitive nictotinic cholinergic antagonist. J Clin Invest 1997; 100: 1623-33.
14. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986; 324: 476-8.
15. Yamori Y. Development of the spontaneously hypertensive rat (SHR) and of various rat models, and their implications. In: DeJong W, editor. Handbook of hypertension. Vol. 4. Experimental and genetic models of hypertension. Amsterdam: Elsevier Science Publishers B.V., 1984: 224-39.
16. Tanase H, Suzuki Y, Ooshima A, Yamori Y, Okamoto K. Genetic analysis of blood pressure in spontaneously hypertensive rats. Jpn Circ J 1970; 34: 1197-212.
17. Casto R, Printz M. Genetic transmission of hyper-responsivity in crosses between spontaneously hypertensive and Wistar-Kyoto rats. J Hypertension 1988; 6(Suppl 4): S52-4.
18. Kurtz TW, Casto R, Simonet L, Printz MP. Biometric genetic analysis of blood pressure in the spontaneously hypertensive rat. Hypertension 1990; 16: 718-24.
19. Michel MC, Jager S, Casto R, et al. On the role of renal alpha-adrenergic receptors in spontaneously hypertensive rats. Hypertension 1992; 19: 365-70.
20. Schlager G. Genetic hypertension in mice. In: Ganten D, DeJong W, editors. Handbook of hypertension. Vol. 16. Experimental and genetic models of hypertension. Amsterdam: Elsevier Science, 1994: 158-72.
21. Schlager G. Biometrical genetic analysis of blood pressure level in the genetically hypertensive mouse. Clin Exp Hypertens 1994; 16: 809-24.
22. Takiyyuddin MA, DeNicola L, Gabbai FB, et al. Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary hypertension. Hypertension 1993; 21: 674-9.
23. Barbosa JA, Gill BM, Takiyyuddin MA, O'Connor DT. Chromogranin A: post-translational modifications in secretory granules. Endocrinology 1991; 128: 174-90.
24. Parmer RJ, Koop AH, Handa MT, O'Connor DT. Molecular cloning of chromogranin A from rat pheochromocytoma cells. Hypertension 1989; 14: 435-44.
25. Simon-Chazottes D, Wu H-J, Parmer RJ, et al. Assignment of the chromogranin A locus to homologous regions on mouse chromosome 12 and rat chromosome 6. Genomics 1993; 17: 252-5.
26. Mahata SK, Kozak CA, Szpirer J, et al. Dispersion of chromogranin/secretogranin secretory protein family loci in mammalian genomes. Genomics 1996; 33: 135-9.
27. Serikawa T, Kuramoto T, Hilbert P, et al. Rat gene mapping using PCR-analyzed microsatellites. Genetics 1992; 131: 701-21.
28. Bradford MM. A rapid and sensitive methods for quantitating microgram quantities of proteins utilizing the principle of protein dye binding method. Anal Biochem 1976; 72: 248-54.
29. Ziegler MG, Woodson LC, Kennedy BP. Radioenzymatic assay of catecholamines, metabolites, and related enzymes. In: Krstulovic AM, editor. Quantitative analysis of catecholamines and related compounds. New York: Halsted Press, 1986: 263-80.
30. Nagatsu T, Udenfriend S. Photometric assay of dopamine beta-hydroxylase in human blood. Clin Chem 1972; 18: 980-3.
31. Stansfield WD Genetics. 2nd ed. Schaum's outline series. New York: McGraw-Hill, 1983.
32. Judy WV, Watanabe AM, Murphy WR, Aprison BS, Yu PL. Sympathetic nerve activity and blood pressure in normotensive backcross rats genetically related to the spontaneously hypertensive rat. Hypertension 1979; 1: 598-604.
33. Touw KB, Haywood JR, Shaffer RA, Brody MJ. Contribution of the sympathetic nervous system to vascular resistance in conscious young and adult spontaneously hypertensive rats. Hypertension 1980; 2: 408-18.
34. Barker D, Schafer M, White R. Restriction sites containing CpG show a higher frequency of polymorphism in human DNA. Cell 1984; 36: 131-8.
35. Lander ES, Botstein D. Mapping Mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics 1989; 121: 185-99.
36. Hilbert P, Lindpaintner K, Beckmann JS, et al. Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats. Nature 1991; 353: 521-9.
37. Jacob HJ, Lindpaintner K, Lincoln SE, et al. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell 1991; 67: 213-24.
38. Ely D, Caplea A, Dunphy G, et al. Spontaneously hypertensive rat Y chromosome increases indexes of sympathetic nervous system activity. Hypertension 1997; 29: 613-8.
39. Tang K, Wu H, Mahata SK, Taupenot L, Parmer RJ, O'Connor DT. Stimulus-transcription coupling in pheochromocytoma cells. Promoter region-specific activation of chromogranin A biosynthesis. J Biol Chem 1996; 271: 28382-90.
40. Tang K, Wu HJ, Mahata SK, et al. Stimulus coupling to transcription vs secretion in pheochromocytoma cells: convergent and divergent signal transduction pathways, and the crucial roles for route of cytosolic calcium entry and protein kinase C. J Clin Invest 1997; 100: 1180-92.
41. Tang K, Wu H, Mahata SK, O'Connor DT. A crucial role for the mitogen-activated protein kinase pathway in nicotinic cholinergic signaling to secretory protein transcription in pheochromocytoma cells. Mol Pharmacol 1998; 54: 59-69.
42. Schober M, Howe PR, Sperk G, Fischer-Colbrie R, Winkler H. An increased pool of secretory hormones and peptides in adrenal medulla of stroke-prone spontaneously hypertensive rats. Hypertension 1989; 13: 469-74.
43. Rapp JP. A Mendelian locus controlling vascular smooth muscle response in spontaneously hypertensive rats. In: Rascher W, Clugh D, Ganten D, editors. Hypertensive mechanisms: the spontaneously hypertensive rat as a model to study human hypertension. Proceedings of the 4th International Symposium on Rats with Spontaneous Hypertension and Related Studies, Heidelberg, 1-4 September 1981. Stuttgart: FK Schattauer Verlag, 1982: 134-8.
44. Mahata SK, Mahata M, Wu H, Parmer RJ, O'Connor DT. Neurotrophin activation of catecholamine storage vesicle protein gene expression: signaling to chromogranin A biosynthesis. Neuroscience 1999; 88: 405-24.
45. Ueyama T, Hamada M, Hano T, Nishio I, Masuyama Y, Furukawa S. Increased nerve growth factor in spontaneously hypertensive rats. J Hypertension 1992; 10: 215-9.
46. Charchar FJ, Kapuscinski MK, Harrap SB. Nerve growth factor locus explains elevated renal nerve growth factor mRNA in young spontaneously hypertensive rats. Hypertension 1998; 32: 705-9.
47. Kapuscinski M, Charchar F, Mitchell GA, Innes B, Harrap SB. Nerve growth factor gene and genetic hypertension in spontaneously hypertensive rats. J Hypertension 1996; 14: 191-7.
48. Brock JA, Van Helden DF, Dosen P, Rush RA. Prevention of high blood pressure by reducing sympathetic innervation in the spontaneously hypertensive rat. J Auton Nerv Syst 1996; 61: 97-102.
49. Fischer-Colbrie R, Iacangelo A, Eiden LE. Neural and humoral factors separately regulate neuropeptide Y, enkephalin, and chromogranin A and B mRNA levels in rat adrenal medulla. Proc Natl Acad Sci U S A 1988; 85: 3240-4.
50. Rozansky DJ, Wu HJ, Tang K, Parmer RJ, O'Connor DT. Glucocorticoid activation of chromogranin A gene expression: identification and characterization of a novel glucocorticoid response element. J Clin Invest 1994; 94: 2357-68.
51. Yamori Y. 1982. Pathogenetic similarities and differences among various strains of spontaneously hypertensive rats. In: Rascher W, Clugh D, Ganten D, editors. Hypertensive mechanisms: the spontaneously hypertensive rat as a model to study human hypertension. Proceedings of the 4th International Symposium on Rats with Spontaneous Hypertension and Related Studies, Heidelberg, 1-4 September 1981. Stuttgart: FK Schattauer Verlag, 1982: 66-95.
52. Schork NJ, Nath SP, Lindpaintner K, Jacob HJ. Extensions to quantitative trait locus mapping in experimental organisms. Hypertension 1996; 28: 1104-11.
53. Ebert SN, Ficklin MB, Her S, et al. Glucocorticoid-dependent action of neural crest factor AP-2: stimulation of phenylethanolamine N-methyltransferase gene expression. J Neurochem 1998; 70: 2286-95.
54. Grobecker H, Roizen MF, Weise V, Saavedra JM, Kopin IJ. Sympathoadrenal medullary activity in young, spontaneously hypertensive rats. Nature 1975; 258: 267-8.
55. Slotkin TA, Green HO. Adrenal medullary storage vesicles of the spontaneously hypertensive rat. Biochem Pharmacol 1975; 24: 173-80.